Metraipolis › archive › dc_82ef111b4620
Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations — Europe PMC PMID:42122267
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42122267
- DOI
- 10.3390/cancers18091471
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T20:11:05.160Z
- SHA-256 of the archived text
debe9b920ba87b43a2aa4120bf80946f1f6cc95e5a37642db57bc01aebf43c11- Stable URL of this page
https://metraipolis.com/documento/dc_82ef111b4620
How to cite
Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations — Europe PMC PMID:42122267 — Europe PMC (en), https://europepmc.org/article/MED/42122267 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_82ef111b4620 (Metraipolis archive dc_82ef111b4620, sha256 debe9b920ba87b43a2aa4120bf80946f1f6cc95e5a37642db57bc01aebf43c11)
BibTeX
@misc{dc82ef111b4620,
title = {Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations — Europe PMC PMID:42122267},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42122267},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_82ef111b4620; sha256 debe9b920ba87b43a2aa4120bf80946f1f6cc95e5a37642db57bc01aebf43c11},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42122267. Agents can read the archived copy with the MCP tool read_document.